Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings

CRBP· Manufacturing· Fiscal year ends in December

CEO pay in FY2023Stock +82.2% in FY2023

Yuval Cohen is the CEO of Corbus Pharmaceuticals Holdings and was paid $1.1M in FY2023 (Dec), down 21%.

Pay$100 in the stock at the end of FY21 → $33
CEO pay is from each Corbus Pharmaceuticals Holdings proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Dominic SmethurstFY2025
  2. 2Yuval CohenFY2023
  3. 3Sean MoranFY2023

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Corbus Pharmaceuticals Holdings paid its one named executive on file $1.8M in FY2025 (Dec).

Name
Dominic SmethurstChief Medical Officer
Yuval CohenChief Executive OfficerNot disclosedNot disclosed
Sean MoranChief Financial OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Corbus Pharmaceuticals Holdings. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Activity

Filings6

See all
Proxy statementDEF 14AApr 2, 2026FY2025
Annual report10-KMar 9, 2026FY2025
Proxy statementDEF 14AApr 1, 2025FY2024
Annual report10-KMar 11, 2025FY2024
Proxy statementDEF 14AApr 2, 2024FY2023
Annual report10-KMar 12, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data